Updated July 8, 2026: This piece originally described Sage Therapeutics’ strategic alternatives as unresolved. Supernus Pharmaceuticals completed its acquisition of Sage on July 31, 2025, at $8.50 per share in cash plus one contingent value right worth up to $3.50 per share. Sage shares were delisted from Nasdaq following the close. The article has been corrected to reflect that outcome.

When the FDA approved zuranolone (Zurzuvae) for postpartum depression in 2023 while declining to approve it for major depressive disorder, the agency made a defensible scientific decision and an indefensible commercial one. The science was contested but reasonable: the MDD program produced modest effect sizes and one failed pivotal trial. The commercial structure that resulted has now produced exactly the outcome a more sophisticated review would have anticipated.

The structural trap

A PPD-only label creates several intersecting constraints that compound rather than offset each other.

First, the addressable patient population is small. PPD prevalence is substantial in absolute terms, but the diagnosed and pharmacologically treated population is a fraction of that. Most postpartum depression is managed by SSRIs through obstetric and primary care channels, not by psychiatry referrals.

Second, the prescribing pathway is fragmented. Obstetricians, who see PPD patients most directly, are not typically comfortable prescribing a novel neurosteroid. Psychiatrists, who would be, are not typically the first clinician a postpartum patient sees.

Third, the price point that supports an innovative drug program is incompatible with the volume that an obstetrics channel can deliver. Sage and partner Biogen priced Zurzuvae at roughly $16,000 for a 14-day course: a price the science arguably supports but the commercial structure cannot sustain on PPD volume alone.

What actually happened

Sage’s publicly signaled exploration of strategic alternatives ended in an acquisition, not a turnaround. Supernus Pharmaceuticals completed its purchase of Sage Therapeutics on July 31, 2025, at $8.50 per share in cash plus one contingent value right worth up to $3.50 per share. Sage shares were delisted from Nasdaq following the close, and the additional neurosteroid programs referenced in the original analysis are now part of Supernus, not an independent company’s pipeline. The SAGE-718 / dalzanemdor cognitive-disorders program had already been discontinued in November 2024 after Phase 2 failures.

The acquisition is the outcome this piece flagged as the realistic one: a strategic acquirer solving the channel fragmentation problem and rationalizing the cost structure of a clinical-stage company carrying commercial overhead a PPD-only label could not support. Supernus now holds Sage’s side of the Zurzuvae collaboration. Biogen’s role is unchanged: the drug’s U.S. economics still run through the original Sage-Biogen collaboration, with Supernus now stepping into Sage’s position.

The generalizable lesson

The mistake to learn from is not narrowly Sage’s. Several upcoming psychedelic and rapid-acting antidepressant programs face the same indication-versus-label question. A “go for the narrowest indication that gets approved” strategy, which has worked beautifully in oncology, does not work the same way in psychiatry. Psychiatric labels require commercial infrastructure that scales with patient volume, and the channels are not interchangeable across indications.

Sponsors mid-stream in MDD and TRD programs should be reading the Sage outcome closely. The wrong narrow-indication strategy can produce an asset that is scientifically valid and commercially trapped.